Search for a trial

The use of Progentix TCP (beta-tricalciumphosphate) as a bone substitute in defects originated from curettage of benign bone tumors

In patients with benign bone tumors, the defect originated from curretage of the tumor, will be filled with Progentix TCP. The bone regenerative capacity of Progentix TCP will be compared to the capacity of autologous bone (the golden standard).…

AN OPEN-LABEL, SINGLE SEQUENCE, CROSSOVER DRUG-DRUG
INTERACTION STUDY ASSESSING THE EFFECT OF PEXIDARTINIB ON THE PHARMACOKINETICS OF CYP3A4 AND CYP2C9 SUBSTRATES IN PATIENTS

Primary ObjectivesTo assess the effects of pexidartinib on the PK parameters of single-dose midazolam and tolbutamide in patients.Secondary ObjectivesTo evaluate:- To determine the overall response rate (ORR) in patients with TGCT,kit-mutant…

A Phase 1/2 Study of FPA008, an anti-CSF1 Receptor Antibody, in Patients with Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT)

Primary- Phase 1: To determine the recommended dose (RD) of cabiralizumab in patients with pigmented villonodular synovitis (PVNS)/diffuse type tenosynovial giant cell tumor (dt-TGCT)- Phase 2: To estimate the objective response rate (ORR = CR+PR)…

An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Rich Tumors of Bone.

Primary:Subjects with salvageable giant cell rich tumors:- To evaluate subjects who do not require surgery during the study- To evaluate subjects who are able to undergo a less morbid surgical procedure compared with the planned surgical procedure…